Table 4.
Mixed-Effects Model for Repeated Measures (MMRM) analysis on clinical and functioning outcomes in patients with combined treatment or medication treatment a
| Assessment | Mean (95% CI) | Analyses b | ||||||
|---|---|---|---|---|---|---|---|---|
| baseline | 6 months | 12 months | Group-by-Time Interaction Effect |
|||||
| CT (n=580) |
MT (n=604) |
CT (n=512) |
MT (n=472) |
CT (n=406) |
MT (n=338) |
F | p | |
| PANSS | 44.6(43.5–45.7) | 45.3(44.2–46.5) | 37.3(36.5–38.1) | 38.8(38.0–39.7) | 34.7(34.2–35.2) | 36.4(35.7–37.1) | 0.406 | 0.81 |
| ITAQ | 12.8(12.4–13.2) | 12.7(12.2–13.1) | 17.9(17.5–18.3) | 14.2(13.7–14.8) | 19.5(19.1–19.8) | 15.9(15.4–16.5) | 25.945 | <0.001 |
| GAS | 74.1(73.2–75.1) | 74.2(73.2–75.1) | 79.8(78.9–80.6) | 77.9(77.0–78.8) | 82.9(82.0–83.7) | 80.8(79.9–81.8) | 4.332 | 0.002 |
| ADL | 17.2(17.0–17.4) | 17.2(17.0–17.4) | 15.7(15.5–15.8) | 16.6(16.5–16.8) | 15.4(15.3–15.5) | 16.4(16.3–16.5) | 12.699 | <0.001 |
| SF-36 | ||||||||
| Physical Functioning | 90.8(89.7–91.8) | 90.6(89.5–91.6) | 92.9(91.8–93.9) | 92.3(91.3–93.2) | 95.2(94.3–96.1) | 94.9(94.1–95.7) | 0.121 | 0.87 |
| Role-Physical | 54.1(50.8–57.3) | 57.3(54.1–60.6) | 67.1(63.9–70.2) | 65.8(62.5–69.2) | 78.1(74.9–81.3) | 73.4(69.6–77.1) | 5.129 | 0.006 |
| Bodily Pain | 77.2(74.7–79.8) | 78.8(76.4–81.2) | 83.0(80.5–85.6) | 84.4(81.9–86.9) | 89.9(87.9–91.9) | 89.3(87.0–91.6) | 2.795 | 0.06 |
| General Health | 61.7(60.3–63.2) | 63.5(62.1–65.0) | 67.5(66.1–69.0) | 65.8(64.2–67.4) | 71.3(69.8–72.8) | 67.9(66.2–69.7) | 11.094 | <0.001 |
| Vitality | 59.5(58.0–61.1) | 58.0(56.4–59.5) | 65.6(64.1–67.1) | 60.1(58.4–61.9) | 66.7(65.0–68.4) | 60.5(58.4–62.7) | 5.327 | 0.005 |
| Social Functioning | 74.5(72.5–76.5) | 74.5(72.6–76.4) | 82.2(80.4–84.0) | 81.2(79.3–83.0) | 86.5(84.5–88.4) | 85.0(82.9–87.1) | 1.003 | 0.37 |
| Role-Emotional | 57.5(54.2–60.7) | 56.5(53.1–59.8) | 68.0(64.7–71.2) | 63.8(60.2–67.4) | 80.1(76.9–83.2) | 72.1(68.1–76.1) | 3.985 | 0.02 |
| Mental Health | 65.2(63.8–66.6) | 64.5(63.2–65.8) | 69.1(67.7–70.6) | 67.2(65.8–68.6) | 71.9(70.4–73.5) | 70.2(68.5–71.8) | 1.573 | 0.21 |
Abbreviation: CI, confidence interval; PANSS, the Positive and Negative Syndrome Scale; ITAQ, Insight and Treatment Attitudes Questionnaire; SF-36, Medical Outcome Study Short-Form 36-item questionnaire; GAS, Global Assessment Scale; ADL, the Activities of Daily Living Scale; CT, combined treatment; MT, medication treatment.
Analyses are based on Mixed-Effects Model for Repeated Measures (MMRM) in unstructured variance matrix. Baseline value was included as covariates.
Analyses used data from the baseline, 3, 6, 9, and 12 month assessments, only the baseline, 6 and 12 month results were presented in the table.